AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Tessera therapeutics stocks12/21/2023 ![]() “I look forward to working with the Tessera team to find new ways to cure rare genetic diseases at their source.”įor more information on Tessera, including how Gene Writing works, partnership opportunities, and job openings, visit About Tessera Therapeutics “With its pioneering and versatile Gene Writing technology, Tessera Therapeutics is at the very forefront of genetic medicine,” said Dr. in Mathematics from Stony Brook University. Guey served in senior leadership roles for Moderna, Xilio Therapeutics, Shire, and Pfizer. Guey brings over 13 years of drug development experience in program leadership, research and nonclinical development, pharmacogenomics and epidemiology. Guey, Tessera’s Senior Vice President of Rare Diseases Program Strategy and Operations, will oversee the execution of Tessera’s genetic medicine programs in Rare Diseases. I’m excited to help shape Tessera Therapeutics, whose Gene Writing technology has the potential to address many of the limitations of current genetic medicine technologies,” said Dr. “As medicine continues to move up the central dogma of molecular biology from proteins to mRNA to DNA, the opportunity to cure diseases will continue to expand. in Chemical Engineering from the University of Delaware and his M.B.A. Pujar spent 18 years at Merck & Co., developing and commercializing vaccines and biologics. Pujar served as Chief Technology Officer at Spark Therapeutics, a pioneer in AAV gene therapy, and Head of Technical Development and Manufacturing at Moderna, where he led mRNA and lipid nanoparticle development and manufacturing. Pujar brings more than 20 years of drug development, manufacturing and commercialization experience spanning AAV gene therapy, mRNA vaccines and therapeutics, and traditional vaccines and biologics. Pujar, an Operating Partner at Flagship Pioneering since October 2020, will also serve as Tessera’s Chief Operating Officer. I am honored to help move this vision forward.”ĭr. “By harnessing the power of mobile genetic elements, Tessera’s Gene Writing platform is poised to realize the full potential of genetic medicine and make an unprecedented impact on human health. I am excited to join the team at Tessera Therapeutics to bring innovative Gene Writing therapies into the clinic,” said Dr. “I have been privileged to lead the clinical development of gene therapy programs from inception through approval to deliver these transformative medicines to patients with life-threatening diseases. He completed a fellowship in infectious diseases at the Harvard Longwood Combined ID Program, his residency training in internal medicine, and an endocrinology research fellowship at the University of Chicago Hospitals. Davidson led clinical research for a wide range of therapeutic programs at Genzyme and GelTex, spanning biologics, polymers, and gene therapy. Davidson served as Chief Medical Officer of bluebird bio, where he played a critical role in advancing a broad genetic medicine pipeline across blood disorders, rare diseases and oncology, successfully leading numerous genetic medicine programs into the clinic and delivering multiple first-in-class approvals for genetic medicines in the U.S. ![]() Davidson brings over 20 years of expertise in clinical drug development focused on rare diseases and gene therapy to his new role as Tessera’s Chief Medical and Development Officer. “Together and alongside our current senior leadership team, they will be instrumental in advancing Tessera’s mission to bring forth innovative and curative medicines that go beyond the limitations of current technologies.”ĭr. Geoffrey von Maltzahn, CEO and Co-Founder of Tessera. “David, Hari and Lin all bring a wealth of strategic leadership and deep expertise to Tessera at an exciting time in our growth,” said Dr. The senior appointments come just two months after the company announced over $230 million in Series B fundraising in January and will be key to advancing the company’s Gene Writing platform and accelerating development of multiple therapeutic programs. as Senior Vice President of Rare Diseases Program Strategy and Operations. as Chief Operating Officer, and Lin Guey, Ph.D. as Chief Medical and Development Officer, Hari Pujar, Ph.D. Tessera Therapeutics, a biotech company pioneering Gene Writing, announced today the appointment of David Davidson, M.D.
0 Comments
Read More
Leave a Reply. |